Health
Genethon develops gene therapy for treating Duchenne muscular dystrophy – News-Medical.net
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM,…
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004.
This trial’s goal is to assess the safety and efficacy of an innovative gene therapy designed at Genethon, combining an AAV-type viral vector…
-
Business23 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Noosa News23 hours agoThe Almond Ashes sees Australia and India mix business and cricket
-
General23 hours agoUK PM ready to ‘shelter’ businesses from tariff storm
-
General23 hours agoWhy do states and territories have different school holidays?